New MRI dye aims to sharpen prostate cancer detection

NCT ID NCT06226129

Terminated Diagnosis Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study tests a new contrast agent called Gadopiclenol (Elucirem) for MRI scans of the prostate. The goal is to see if it makes aggressive prostate cancers stand out more clearly, helping doctors decide who needs a biopsy. About 150 men scheduled for a prostate MRI will receive this agent, and radiologists will rate the image quality. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gadopiclenol (a contrast agent for MRI)
What this could lead to: If successful, this could lead to more accurate MRI scans for prostate cancer, helping doctors better identify aggressive tumors and reduce unnecessary biopsies.
What could go wrong: This is a Phase 4 study focused on imaging quality, not treatment. The new agent may not significantly improve detection over existing contrast agents, and gadolinium-based agents carry a small risk of allergic reactions or kidney-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Columbia University Irving Medical Center

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.